750
Background: Cognitive impairment has been reported for patients receiving chemotherapy; however, the data is limited with respect to 5FU/oxaliplatin based therapy in colorectal cancer patients. We conducted a pilot study to determine if there was cognitive or mobility impairment in patients receiving adjuvant 5Fu/oxaliplatin chemotherapy. Methods: At baseline, end of chemotherapy and 6 months post chemotherapy, participant completed a neuropsychological test battery, which included the Stroop, Hopkins Verbal Learning Test-Revised (HVLT-R), and Trail Making A & B (TMT A&B), a 6-minute walk test (6MWT), a measure of physical function, and a functional mobility testing battery, which included timed up and go (TUG) and gait speed. Demographic information and self-reported physical activity, using the International Physical Activity Questionnaire (IPAQ), were also collected at these time points. For the analysis of neuropsychological and mobility test scores, the paired t-test was used to test for the differences and assess the change in the mean scores from the baseline, 6-months and 12 months. Results: 13 patients were enrolled, 10 have completed the 12 month evaluation. No significant changes were noted in the HVLT-R, Stroop, and TMT-A and -B mean scores after completion of chemotherapy compared to baseline. Compared to baseline, no significant changes were observed for 6MWT, TUG, GS, or leisure-time physical activity after completion of chemotherapy. Conclusions: In this small pilot study, there were no significant changes in chemotherapy-associated cognitive, physical function, or functional mobility noted from baseline to the end of chemotherapy. In addition, physical activity levels and average time spent sitting did not change significantly.